ANZCTR search results

The purpose of this study is to investigate the effectiveness of values-focused interventions for mental health support workers on their uptake of newly-acquired evidence-based recovery practices. Main hypothesis: Staff who participate in values-focused interventions (i.e. clarification during training and 12 x 1 monthly values-based coaching) will have higher rates of transfer than those in the control (implementation) condition.

Hip fracture is a major cause of death and loss of independence for older people. Exercise prescription after hip fracture is vital to return the patient to the highest possible level of function. Previous studies have shown that older people have difficulty in adhering to exercise programs. This pilot project aims to investigate whether providing the older person with a personalised DVD of their exercises will help them to adhere to the program

The ANTISEPSIS study will investigate whether the low doses of aspirin being trialled in the randomised controlled ASPREE study work to reduce the severity of infection in the patients who have been taking aspirin. There are numerous pieces of information from test tube and laboratory animal studies that show us that low dose aspirin helps to reduce inflammation which contributes to the disease caused by severe infection. If we can show that low dose aspirin safely reduces the severity of infection in elderly patients we will be able to recommend that it should be taken in all patients who are not at high risk of side effects of this drug. We hypothesise that severe outcomes relating to sepsis in the elderly may be prevented by daily low-dose aspirin. We have the opportunity to test this hypothesis through a substudy of the ASPirin in Preventing Events in the Elderly (ASPREE) trial. ASPREE is a major, Australian/US randomised controlled primary prevention trial of low dose aspirin in the elderly. Our aims are to use the ASPREE randomised controlled trial (RCT) framework and extend data collection relating to sepsis events in its participants to assess our primary endpoint: reduction of deaths contributed to by sepsis in participants receiving aspirin versus placebo. We will also conduct an analysis of two secondary endpoints: reduction of severe infection episodes requiring hospital admissions reduction of ICU admissions among patients hospitalised for severe sepsis The ASPREE study, which will provide a sufficient sample size to assess our primary outcome, represents an ideal chance to assess the impact of aspirin on outcomes of sepsis in the trial population of elderly participants.

Placenta praevia remains a significant cause of peri-partum morbidity. It is associated with an increased risk of postpartum haemorrhage and subsequent surgical procedures to control bleeding including caesarean hysterectomy. The use of the Bakri balloon prophylactically at the time of caesarean section may provide a significant benefit in reducing blood loss and avoiding the need for other more extensive surgical procedures.

In order to reduce the effects of age-associated memory impairment (AAMI) the Phospholipid Intervention for Cognitive Ageing Reversal (PLICAR) was developed so as to test the efficacy of a milk protein concentrate rich in phospholipids (Lacprodan(Registered Trademark) PL-20) for the improvement of cognitive function in elderly individuals with AAMI. ). On the basis of previous human clinical studies with bovine and plant-derived phospholipids, it is hypothesised that Lacprodan(Registered Trademark) PL-20 supplementation over 180 days will result in significant improvements to memory and other cognitive functions.

This study is evaluating Lenalidomide induction chemotherapy, autologous peripheral stem cell transplant, and adjuvant vaccination with autologous dendritic cells and lenalidomide maintenance in patients with multiple myeloma. Who is it for? You may be eligible to join this study if you are aged above 18 years and have a bone marrow biopsy confirmed diagnosis of multiple myeloma (MM). Trial details Doctors are looking for better ways to improve the duration that the myeloma remains under control. Previous research within Australia and internationally has shown that many blood diseases may be controlled by utilizing the body’s own immune system to fight the abnormal cells. It is possible this may be the case with the vaccine therapy included in this study. In this research project, the researchers will test whether giving a vaccine of immune stimulating cells after treatment with lenalidomide and transplantation followed by lenalidomide maintenance treatment is better than treatment with lenalidomide and transplantation alone or the current standard chemotherapy treatment with transplantation. Lenalidomide is a man-made drug that alters and stimulates the immune system, causes abnormal plasma cells to die, and it may also interfere with the development of tiny blood vessels that help support myeloma cell growth. The researchers running this study believe that the use of lenalidomide may be the best way of controlling myeloma initially and may enhance the effect of the vaccine. The vaccine used in this study is manufactured using a sample of your myeloma cells combined with immune stimulating cells known as dendritic cells. Dendritic cells are normal immune stimulating cells found in everyone. We have the ability to produce large numbers of these cells in the laboratory from your normal white blood cells. We believe that the combination of large number of dendritic cells carrying fragments of the abnormal myeloma cells may be able to increase your immune system’s ability to fight the myeloma cells, which remain after the initial lenalidomide therapy and bone marrow transplant. This vaccine is an experimental treatment. This means that it is not an approved treatment for myeloma in Australia or other parts of the world. This means that it must be tested to see if it is an effective treatment for myeloma. A total of 22 people will take part in the initial research project. 12 people will actively participate in the vaccination part of the study, whilst the other 10 will act as a control group who have treatment with lenalidomide and transplantation for their myeloma and can be compared to the vaccinated group to see if there are any differences between them. A further 20 patients will be recruited into the study to examine the effects of different doses of lenalidomide with or without steroids on the immune system. Thus a total of 42 patients in total will be enrolled.

The purpose of the study is to compare the extent of refractive change in patients receiving HBOT via hood vs mask. The results will aid in the understanding of the etiology of HBOT induced myopia, and aid in choosing the delivery method of HBOT in future treatment sessions. The investigators hypothesise greater refractive change in the hooded group, in keeping with results of previous studies.

This study will attempt to determine what causes distress in lung cancer and mesothelioma patients and whether having access to an interdisciplinary team reduces this distress. Who is it for? You may be eligible to join this study if you are 18 years or over with lung cancer or mesothelioma, and currently under the care of any/all medical oncologist, respiratory physician, radiation therapist, palliative care specialist at Sir Charles Gairdner Hospital. Trial details: Participants in this trial will receive access to allied health staff (including Social worker, Physiotherapist, Occupational Therapist, Dietitian and Clinical Nurse) who can assist them with strategies for reducing or managing their concerns. The overall duration of this study will be 6 months in which we will aim to assess all patients with a new diagnosis of lung cancer or mesothelioma and existing patients as required. Study aims: To compare distress in lung cancer and mesothelioma patients before and after having access to a team of allied health staff to address their concerns.

Diseases such as Scleroderma, Multiple Sclerosis (MS), Systemic Lupus Erythematosus (SLE), vasculitis, Chrohn’s disease, Behcet’s disease refractory to all available therapies and in the opinion of the referring physician, HSCT is a valid therapeutic option for that patient. These patients will require an independent physician to assess the patient’s suitability for HSCT. Patients will undergo GSCF stimulated stem cell collection following chemotherapy. Patients are readmitted for autlogous transplant and will have specific high dose immunosuppresssive therapy depending on their disorder followed by stem cell re infusion

This study aims to evaluate the effect of haploidentical donor stem cell transplantation in patients with haematological malignancies. Who is it for? You may be eligible to join this study if you are aged between 16-50 years and have ongoing complete remission of underlying haematological malignancy. You should have available a haploidentical family donor. This is a donor who is a 50% match, and can be a parent, sibling or child. Trial details All participants in this trial will undergo ten days of chemotherapy treatment, followed by infusion of peripheral blood stem cells (PBSCs) from the donor into the vein (i.e. intravenously). Participants will also be administered a number of medications to prevent graft versus host disease (GVHD), which is a common complication following stem cell transplantation. Patients will be regularly assessed for up to 12 months in order to evaluate clinical efficacy and safety of treatment.